Business Description
EQL Pharma AB
ISIN : SE0005497732
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.08 | |||||
Equity-to-Asset | 0.47 | |||||
Debt-to-Equity | 0.75 | |||||
Debt-to-EBITDA | 3.11 | |||||
Interest Coverage | 5.73 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 5.66 | |||||
Beneish M-Score | -1.57 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 13.8 | |||||
3-Year EBITDA Growth Rate | 55.3 | |||||
3-Year EPS without NRI Growth Rate | 26.1 | |||||
3-Year Book Growth Rate | 24.9 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 26.93 | |||||
9-Day RSI | 45.58 | |||||
14-Day RSI | 52.97 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.24 | |||||
Quick Ratio | 0.47 | |||||
Cash Ratio | 0.06 | |||||
Days Inventory | 229.07 | |||||
Days Sales Outstanding | 64.14 | |||||
Days Payable | 83.71 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | -0.01 |
Profitability Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 43.19 | |||||
Operating Margin % | 15.07 | |||||
Net Margin % | 9.85 | |||||
FCF Margin % | -28.84 | |||||
ROE % | 17.26 | |||||
ROA % | 8.56 | |||||
ROIC % | 12.33 | |||||
ROC (Joel Greenblatt) % | 39.35 | |||||
ROCE % | 22.41 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 150 | |||||
PE Ratio without NRI | 150 | |||||
PEG Ratio | 2.04 | |||||
PS Ratio | 5.29 | |||||
PB Ratio | 8.37 | |||||
Price-to-Tangible-Book | 172.89 | |||||
EV-to-EBIT | 36.01 | |||||
EV-to-EBITDA | 36.01 | |||||
EV-to-Revenue | 5.42 | |||||
EV-to-FCF | -19.25 | |||||
Price-to-Projected-FCF | 138.93 | |||||
Price-to-Median-PS-Value | 0.92 | |||||
Price-to-Peter-Lynch-Fair-Value | 5.85 | |||||
Price-to-Graham-Number | 33.68 | |||||
Price-to-Net-Current-Asset-Value | 222.29 | |||||
Earnings Yield (Greenblatt) % | 2.78 | |||||
FCF Yield % | -5.65 | |||||
Forward Rate of Return (Yacktman) % | 19.2 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
EQL Pharma AB Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil kr) | 316.382 | ||
EPS (TTM) (kr) | 1.07 | ||
Beta | 0 | ||
Volatility % | 0 | ||
14-Day RSI | 52.97 | ||
14-Day ATR (kr) | 2.551345 | ||
20-Day SMA (kr) | 79.49 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range (kr) | 49.2 - 86.8 | ||
Shares Outstanding (Mil) | 29.06 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
EQL Pharma AB Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
EQL Pharma AB Stock Events
Event | Date | Price(kr) | ||
---|---|---|---|---|
No Event Data |
EQL Pharma AB Frequently Asked Questions
What is EQL Pharma AB(OSTO:EQL)'s stock price today?
When is next earnings date of EQL Pharma AB(OSTO:EQL)?
Does EQL Pharma AB(OSTO:EQL) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |